Genmab — Februar 2020
-
-
God morgen.
-
Abwehrkampf gegen Leukämie - https://www.welt.de/print/die_welt/article205575129/Abwehrkampf-gegen-Leukaemie.html
-
Maintenance Therapy and Relapse/Refractory Treatment https://www.ajmc.com/post-conference-perspectives/ash2019-myeloma/maintenance-therapy-and-relapserefractory-treatment
-
Ireland - Improving access to cancer drugs - https://www.irishtimes.com/opinion/letters/improving-access-to-cancer-drugs-1.4160471
-
Thx E L. Results from Janssen's B-ALL and T-ALL study should be out late 2020 https://www.clinicaltrials.gov/ct2/show/NCT03384654?term=all+daratumumab&draw=2&rank=2#contacts
-
@pensionisten. : måske kun en huskekage. ;-). Denne Genmab chat er jo kun til store stigninger.
-
God morgen.
-
-
Chief medical officer Merdad Parsey also highlighted the company's effort to bring forward non-cell therapies in immuno-oncology to complement its CAR-T programmes at Kite Pharma. Jefferies' Michael Yee offered specific advice on that front, saying a CD20/CD3 bispecific antibody could be a good fit.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind